Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 13/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931742 | 1.00 | FURIN (0.49) | FURINHTR3AKCNK2SCN2ADRD2 | |
| SCHEMBL26077224 | 0.89 | FURIN (0.40) | FURINALDH1A1 | |
| SCHEMBL21551260 | 0.83 | FURIN (0.45) | FURINHTR3AKCNK2SCN2ADRD2 | |
| SCHEMBL21550983 | 0.83 | GPR119 (0.52) | FURIN | |
| SCHEMBL29891027 | 0.83 | GPR119 (0.52) | FURIN | |
| SCHEMBL21551385 | 0.83 | FURIN (0.68) | FURIN | |
| SCHEMBL30931775 | 0.83 | FURIN (0.68) | FURIN | |
| SCHEMBL28538439 | 0.81 | HRH4 (0.45) | FURINHTR3AKCNK2SCN2ADRD2 | |
| SCHEMBL30931853 | 0.80 | FURIN (0.47) | FURINHTR3A | |
| SCHEMBL21551153 | 0.80 | FURIN (0.47) | FURINHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| CN-112384509-A | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | FURIN 1/4885HTR3A 4838/4885KCNK2 3217/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | FURIN 1/4885HTR3A 4838/4885KCNK2 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.